Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (561-570 of 761) with videos related to

Pageof 77
Sort By:
Journal of the American College of Cardiology|May 30, 2020
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI PatientsDavide Cao, Roxana Mehran, George Dangas, et al.
Circulation. Cardiovascular Interventions|November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|February 15, 2020
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet SubstudyUsman Baber, M Urooj Zafar, George Dangas, et al.
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.
Heart (British Cardiac Society)|February 6, 2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary interventionMatthijs A Velders, Jérémie Abtan, Dominick J Angiolillo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 11, 2021
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery diseaseFrancesco Franchi, Fabiana Rollini, Latonya Been, et al.
Journal of Thrombosis and Thrombolysis|June 14, 2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y<sub>12</sub>-receptor antagonists in patients with acute coronary syndromeAngela Lowenstern, Robert F Storey, Megan Neely, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Journal of the American College of Cardiology|July 6, 2019
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art ReviewDavide Capodanno, Kurt Huber, Roxana Mehran, et al.
Circulation|December 21, 2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Pageof 77

Showing results (561-570 of 761) with videos related to

Sort By:
Pageof 77
Journal of the American College of Cardiology|May 30, 2020
Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI PatientsDavide Cao, Roxana Mehran, George Dangas, et al.
Circulation. Cardiovascular Interventions|November 3, 2016
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Journal of the American College of Cardiology|February 15, 2020
Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet SubstudyUsman Baber, M Urooj Zafar, George Dangas, et al.
Circulation. Cardiovascular Interventions|April 11, 2018
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)Elliott M Groves, Deepak L Bhatt, Philippe Gabriel Steg, et al.
Heart (British Cardiac Society)|February 6, 2016
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary interventionMatthijs A Velders, Jérémie Abtan, Dominick J Angiolillo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 11, 2021
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery diseaseFrancesco Franchi, Fabiana Rollini, Latonya Been, et al.
Journal of Thrombosis and Thrombolysis|June 14, 2017
Platelet-related biomarkers and their response to inhibition with aspirin and p2y<sub>12</sub>-receptor antagonists in patients with acute coronary syndromeAngela Lowenstern, Robert F Storey, Megan Neely, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Journal of the American College of Cardiology|July 6, 2019
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art ReviewDavide Capodanno, Kurt Huber, Roxana Mehran, et al.
Circulation|December 21, 2018
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 UpdateDominick J Angiolillo, Shaun G Goodman, Deepak L Bhatt, et al.
Pageof 77